Humanzyme

HumanZyme, Inc. is the global leader providing high-authenticity recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets.  HumanZyme leverages its proprietary engineered human cells, expression vector, and medium to ensure high-yield production of recombinant proteins with native human post-translational modifications, such as phosphorylation and glycosylation. We are a reputable provider of cytokines and kinase reagents and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide--from academic and government research institutions to biotechnology and pharmaceutical companies.

Currently, HumanZyme offers a number of high-authenticity human protein cytokines, kinases, and phosphatases that conventional production methods either can not produce or cannot economically produce.  We also provide timely and cost-effective contract production of recombinant human proteins from human cells.

Human Cell Expression System: Cost-effective and Scalable Production of High-authenticity Recombinant Human Proteins
Functional activities of human proteins depend on proper folding, phosphorylation, disulfide bridge formation, and proteolytic processing or appropriate glycosylation. Ideally, recombinant human proteins are produced in human cells that are more authentic in terms of both physical properties and biochemical functions. However, the current process of human cell expression requires a large quantity of DNA and medium supplemented with bovine serum. Hence, it is often a daunting task to produce sufficient amount of high quality proteins for drug discovery or diagnostic development (1-100 mg) at acceptable cost. HumanZyme has developed a high yield, cost-effective and versatile system to produce active recombinant human proteins in a human cell line to meet the special needs of the broad scientific community and drug discovery industry.  In this system, we have broken key bottleneck steps to increase protein production and reduce cost, including:

• Engineered human cell line adapted to suspension for growth in serum-free and chemically defined medium
Proprietary expression vectors driven by strong promoters and signal peptides Large scale transient expression with small quantity of DNA Rapid creation of stable human cell lines and adaptation to serum-free medium Short time to scale up production Efficient tag or tag-free purification  

Using this expression system, we have produced a large number of highly active human cytokines, kinases and phosphatases. Our technology is particularly suitable for the production of high-authenticity human proteins in medium scale as research and diagnostic reagents, drug screening targets, and therapeutic proteins for preclinical evaluation.  Key differences of recombinant human protein production in different systems are illustrated below:

Typical glycosylation patterns between human and other expression systems: